To assess the status of IL-1 signaling in MPN patients, we measured IL-1β and IL-1 receptor antagonist (IL-1RA) expression in a cohort of 120 MPN patients with JAK2-V617F mutation and 20 normal controls (NC) (Fig. 1a, b and Supplementary Data 1). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.